OBJECTIVES: Type 2 diabetes (DM2) is increasingly common in HIV-infected individuals. Antiretroviral agents and chronic inflammation may adversely affect glycemic control. However, little is known about the effectiveness of diabetic medical therapy in HIV-infected patients. The objective of this study was to compare the effectiveness of initial diabetic medical therapy in patients with and without HIV infection. DESIGN: A retrospective cohort study was conducted among adults with DM2 initiating diabetic medications within the Centers for AIDS Research Network of Integrated Clinical Systems cohort. METHODS: Generalized estimating equations were used to compare changes in hemoglobin A1c (HbA1c) through the year after initiation of therapy, controlling for baseline HbA1c and demographic and clinical covariates. RESULTS: Two hundred and eighty-six HIV-infected patients and 858 age and sex-matched HIV-uninfected patients initiated diabetic medications during the study period. Overall, patients had an adjusted absolute mean reduction in HbA1c of 1.04% [95% confidence interval (CI) -0.87 to -1.22] during the first year of therapy. HIV-infected patients achieved significantly smaller reductions in HbA1c, with an absolute mean difference of -0.17% (95% CI -0.28 to -0.06; P = 0.003). On subanalyses, HIV-infected patients on a protease inhibitor-based regimen had significantly smaller reductions in HbA1c compared to HIV-uninfected patients (adjusted absolute difference -0.21%, 95% CI -0.35 to -0.08; P = 0.002). CONCLUSION: Patients with HIV infection who initiate diabetic medical therapy achieve smaller reductions in HbA1c than patients without HIV infection in the course of routine clinical care. This less robust response may in part be related to use of antiretrovirals that exacerbate insulin resistance, specifically protease inhibitors.
OBJECTIVES:Type 2 diabetes (DM2) is increasingly common in HIV-infected individuals. Antiretroviral agents and chronic inflammation may adversely affect glycemic control. However, little is known about the effectiveness of diabetic medical therapy in HIV-infectedpatients. The objective of this study was to compare the effectiveness of initial diabetic medical therapy in patients with and without HIV infection. DESIGN: A retrospective cohort study was conducted among adults with DM2 initiating diabetic medications within the Centers for AIDS Research Network of Integrated Clinical Systems cohort. METHODS: Generalized estimating equations were used to compare changes in hemoglobin A1c (HbA1c) through the year after initiation of therapy, controlling for baseline HbA1c and demographic and clinical covariates. RESULTS: Two hundred and eighty-six HIV-infectedpatients and 858 age and sex-matched HIV-uninfectedpatients initiated diabetic medications during the study period. Overall, patients had an adjusted absolute mean reduction in HbA1c of 1.04% [95% confidence interval (CI) -0.87 to -1.22] during the first year of therapy. HIV-infectedpatients achieved significantly smaller reductions in HbA1c, with an absolute mean difference of -0.17% (95% CI -0.28 to -0.06; P = 0.003). On subanalyses, HIV-infectedpatients on a protease inhibitor-based regimen had significantly smaller reductions in HbA1c compared to HIV-uninfectedpatients (adjusted absolute difference -0.21%, 95% CI -0.35 to -0.08; P = 0.002). CONCLUSION:Patients with HIV infection who initiate diabetic medical therapy achieve smaller reductions in HbA1c than patients without HIV infection in the course of routine clinical care. This less robust response may in part be related to use of antiretrovirals that exacerbate insulin resistance, specifically protease inhibitors.
Authors: Zachary T Bloomgarden; Regina Dodis; Catherine M Viscoli; Eric S Holmboe; Silvio E Inzucchi Journal: Diabetes Care Date: 2006-09 Impact factor: 19.112
Authors: Janis V Giorgi; Robert H Lyles; Jose L Matud; Traci E Yamashita; John W Mellors; Lance E Hultin; Beth D Jamieson; Joseph B Margolick; Charles R Rinaldo; John P Phair; Roger Detels Journal: J Acquir Immune Defic Syndr Date: 2002-04-01 Impact factor: 3.731
Authors: Jeroen P H van Wijk; Eelco J P de Koning; Manuel Castro Cabezas; Jos op't Roodt; Jorge Joven; Ton J Rabelink; Andy I Hoepelman Journal: Ann Intern Med Date: 2005-09-06 Impact factor: 25.391
Authors: Li Li; Wei-Yi Cheng; Benjamin S Glicksberg; Omri Gottesman; Ronald Tamler; Rong Chen; Erwin P Bottinger; Joel T Dudley Journal: Sci Transl Med Date: 2015-10-28 Impact factor: 17.956
Authors: Paul Crits-Christoph; Robert Gallop; Elizabeth Noll; Aileen Rothbard; Caroline K Diehl; Mary Beth Connolly Gibbons; Robert Gross; Karin V Rhodes Journal: Am J Manag Care Date: 2018-08 Impact factor: 2.229
Authors: Amanda L Willig; Andrew O Westfall; E Turner Overton; Michael J Mugavero; Greer A Burkholder; David Kim; Eric Chamot; James L Raper; Heidi M Crane; Michael S Saag; James H Willig Journal: AIDS Res Hum Retroviruses Date: 2015-07-23 Impact factor: 2.205
Authors: David E Wallace; Michael A Horberg; Debra A Benator; Alan E Greenberg; Amanda D Castel; Anne K Monroe; Lindsey Powers Happ Journal: AIDS Care Date: 2020-08-18
Authors: Jennifer H Han; Kirsha Gordon; Julie A Womack; Cynthia L Gibert; David A Leaf; David Rimland; Maria C Rodriguez-Barradas; Gregory P Bisson Journal: Diabetes Care Date: 2016-09-15 Impact factor: 19.112
Authors: Alfonso C Hernandez-Romieu; Shikha Garg; Eli S Rosenberg; Angela M Thompson-Paul; Jacek Skarbinski Journal: BMJ Open Diabetes Res Care Date: 2017-01-05
Authors: Amanda L Willig; Allison R Webel; Andrew O Westfall; Emily B Levitan; Heidi M Crane; Thomas W Buford; Greer A Burkholder; James H Willig; Aaron J Blashill; Richard D Moore; W Christopher Mathews; Anne Zinski; Josh Muhammad; Elvin H Geng; Sonia Napravnik; Joseph J Eron; Benigno Rodriguez; Marcas M Bamman; E Turner Overton Journal: Prog Cardiovasc Dis Date: 2020-02-12 Impact factor: 8.194